4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with sb 202190 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Horiuchi, M; Mita, S; Oki, K; Senda, T; Tsuji, F | 1 |
2 other study(ies) available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and sb 202190
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Effects of mitogen-activated protein kinase inhibitors or phosphodiesterase inhibitors on interleukin-1-induced cytokines production in synovium-derived cells.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Calcium-Calmodulin-Dependent Protein Kinases; Cytokines; Dose-Response Relationship, Drug; Humans; Imidazoles; Interleukin-1; Phosphodiesterase Inhibitors; Pyridines; Pyrrolidinones; Quinazolines; Rolipram; Synovial Membrane | 1999 |